Genticel Announces Publication in ‘Clinical Cancer

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Genticel Announces Publication in ‘Clinical Cancer Research’ of Phase 1 Trial Results Supporting Safety, Tolerability and Immunogenicity of GTL001

PARIS and TOULOUSE, France, June 01, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus (HPV), today announced the publication of results from the Phase 1 trial of GTL001 in which the Company’s lead candidate was observed to be generally safe and well-tolerated and to induce a specific immune response in women with normal cytology (NILM 1 ) infected with HPV16 or HPV18. In addition, the study provided initial evidence that GTL001 could promote clearance of HPV16 and HPV18 in this population 2 . The peer-reviewed publication, authored by Prof. Pierre Van Damme, MD, PhD, chairman of the Vaccine & Infectious Disease Institute of the University of Antwerp (Belgium) and entitled “ GTL001, a therapeutic vaccine for women infected with human papillomavirus 16 or 18 and normal cervical cytology: results of a Phase 1 clinical trial ” is available online in Clinical Cancer Research (Clin Cancer Res).

“GTL001 is the only therapeutic vaccine candidate in development for women infected with HPV16 or HPV18 before the onset of cervical cellular anomalies or lesions. This Phase 1 study indicated that, in this population, GTL001 had a satisfactory safety profile and induced an antigen-specific cellular immune response,” said Prof. Pierre Van Damme, principal investigator of the Phase 1 trial and senior author of the publication.

Currently, there is no treatment option for the 93 million women worldwide infected with HPV16 and 18, prior to the onset of cervical lesions or cancer. This therapeutic gap is certainly central to the sustained engagement of both patients and physicians; no dropouts were reported throughout this Phase 1 study despite a demanding enrollment and follow-up examination schedule.

GTL001 was generally safe and well tolerated, a key requirement for further clinical development in this infected yet asymptomatic population. Although this tolerability study was not designed to perform statistical analysis 2 , results also showed the induction of a specific immune response against HPV16 and HPV18 and indicated that GTL001 could promote and sustain viral clearance.

“ We are very pleased to share this publication of these encouraging GTL001 phase 1 data which formed the basis for our decision to initiate our ongoing pan-European Phase 2 trial, ” commented Benedikt Timmerman, PhD., MBA, CEO of Genticel. “ The recently released positive results at 12 months in the normal cytology 1 predefined subgroup of the phase 2 study are consistent with the observations of the phase 1 trial in the same population. Together, they strongly suggest that Genticel’s antigen delivery technology is effective in these subjects who represent the large majority of HPV 16/18 positive women. ”

About GTL001 Phase I Clinical Study (EudraCT No. 2010-018629-21)

The Phase 1 trial objectives were to examine the safety, the tolerability, and the immunogenicity of GTL001 solution and GTL001 powder, with or without imiquimod topical cream application, in women infected by HPV 16, HPV 18 or both, who have normal cytology 1 .

The study enrolled 47 HPV 16/18 positive women at the Vaccine and Infectious Disease Institute (VAXINFECTIO, University of Antwerp, Belgium), after two consecutive normal cytology examinations, in three open-label cohorts and one randomized, placebo-controlled, double-blind cohort.

The overall patient retention rate was 100%.

Results showed that intradermal vaccination with GTL001 plus topical imiquimod has an acceptable safety profile, with local reactions, mostly mild to moderate, being the most reported events. All reactions were transient and the interventions needed were occasionally oral over-the-counter analgesics. The systemic and local reactions induced by GTL001 plus imiquimod were consistent with the pharmacological effects of a vaccine inducing a T-cell response.

Consistent with preclinical studies, GTL001 was found able to induce an E7-specific T-cell response. In post-hoc analyses, HPV16/18 clearance 2 rates were highest in the subjects treated with GTL001 plus imiquimod. Sustained clearance assessed in subjects with virology data after an initial clearance was highest in treated subjects.

In this Clinical Cancer Research publication, Prof. Van Damme and colleagues concluded that these results were promising, thereby enabling the initiation of the ongoing phase 2 trial of GTL001. Prof. Van Damme is the lead investigator of this 24-month phase 2 trial, which has enrolled 236 women in 39 European centers and is more than halfway through completion. 

Please refer to the online publication for detailed results of the phase 1 trial.

_______________________________

1  Normal cytology (NILM): Negative for Intraepithelial Lesion or Malignancy , cytological classification of a normal pap smear, without cellular anomalies or lesions.

2  This phase 1 trial was not designed to detect significant differences in viral clearance and no statistical analysis was performed.

About Clinical Cancer Research 

Clinical Cancer Research is a peer-reviewed journal from the American Association for Cancer Research (AACR). It publishes articles that focus on innovative clinical and translational research bridging the laboratory and the clinic.

More information on www.aacr.org and clincancerres.aacrjournals.org

About Genticel

Aiming to solve a public health issue.

Among the 300 million women around the world currently infected with HPV, 500,000 new cases of cervical cancer are identified each year and 275,000 women succumb to the disease. 70% of cervical cancer cases are caused by 2 HPV types and Genticel aims to eliminate them at an early stage with GTL001, its first-in-class immunotherapeutic candidate. GTL001 is more than halfway through a 24-month proof of concept Phase 2 trial in Europe.

Offering a promising technological platform.

Genticel’s versatile platform, Vaxiclase, is ideally suited for the development of immunotherapies against multiple infectious or cancerous diseases. Genticel’s second candidate, GTL002, is a multivalent HPV immunotherapeutic candidate designed with Vaxiclase. It targets the six most relevant HPV types in terms of global epidemiology and is currently in preclinical development.

Focusing on value creation.

Respectively, the peak sales potentials of GTL001 and GTL002 are estimated at over €1 billion and €2 billion per year. In addition to this attractive HPV product pipeline, Genticel’s versatile technological platform, Vaxiclase, has already generated significant interest in the pharmaceutical industry, as illustrated by the partnership agreement signed in 2015 with the Serum Institute of India Ltd. (SIIL), the world’s largest producer of vaccine doses. This partnership could generate up to $57 million in revenues for Genticel, before royalties on sales. It will enable SIIL to develop acellular multivalent combination vaccines against a variety of infectious diseases, including whooping cough.

For more information, visit us at www.genticel.com

Forward Looking Statement

This press release contains forward-looking statements that are not promises or guarantees and involve substantial risks and uncertainties. The Company’s product candidates have not been approved for sale in any jurisdiction. Among the factors that could cause actual results to differ materially from those described or projected herein are uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical preclinical results may not be predictive of future clinical trial results, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French “Autorité des Marchés Financiers”, including in the Company’s Annual Report for the year ended December 31, 2015 and future filings and reports by the Company which are available on the Company’s website. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Genticel undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information, future events or circumstances or otherwise.  

CONTACT: GENTICEL Valerie Leroy Investor Relations & Corporate Communications + 33 6 33 34 37 30 investors@genticel.com INVESTORS Life Sci Advisors Brian Ritchie +1 212 915 2578 britchie@lifesciadvisors.com MEDIA ALIZE RP Caroline Carmagnol et Florence Portejoie +33 6 64 18 99 59 / +33 6 47 38 90 04 genticel@alizerp.fr

Scroll down for more posts ▼

Top 10 Most Recent News Articles

A. O. Smith's Sustainability Scorecard Has Real Teeth

Updated Category News Views 130

Numbers finally showed up wearing work boots in A. O. Smith’s latest sustainability report. The company says it beat every one of its three environmental targets, and the gaps were not the sort of rounding-error victories corporate communications teams love to polish until they shine. For investors following NYSE:AOS, that deserves a look—not a standing ovation, but a...

Continue Reading
Siteimprove Turns Accessibility Checks Into Agent Spend

Updated Category News Views 153

Accessibility work has usually been the thing teams promise to fix after the launch party is over. Siteimprove is trying to shove that discipline directly into the AI-agent workflow, announcing on November 19, 2026 that its Siteimprove.ai Accessibility Agent is available through Agentic Commerce on AWS Marketplace. The practical hook is simple enough: an AI agent can...

Continue Reading
Small Business Insurance Is a Costly Blind Spot Today

Updated Category News Views 131

A busted pipe, a fender-bender, or one bad fall can turn a promising little company into a very expensive regret. That is the plain-English value in insurance expert Michael Oehrke's overview for HelloNation: small-business insurance is not glamorous, it is not growth marketing, and it is often ignored until the owner is staring at a bill that can chew through years of...

Continue Reading
Lecanemab's Alpha-Syn Signal Deserves a Cooler Head

Updated Category News Views 88

Mixed pathology is where Alzheimer's investing gets uncomfortably real, and this new lecanemab readout is a decent reminder that a drug can show promise without settling the argument. Eisai and Biogen presented a Clarity AD cerebrospinal-fluid substudy at CTAD 2026 examining people with early Alzheimer's disease who also tested positive for alpha-synuclein pathology. The...

Continue Reading
NextPlat’s 150-Patient Test Has a Long Road Ahead

Updated Category News Views 114

A strip of pills can look mundane, yet it is where this entire NextPlat pitch either earns its keep or falls apart. PharmcoRx has signed a partner pharmacy agreement with MedSure Systems for a 150-patient Medicare medication-adherence pilot in South Florida. That is a small starting line, no two ways around it. Still, the mechanics are more interesting than another vague...

Continue Reading
Rafay's Third Fast 500 Nod Tracks AI Cloud Buildout

Updated Category News Views 104

GPU warehouses are easy to admire and brutally hard to operate like a real business. Rafay Systems landing on Deloitte's 2026 Technology Fast 500 for a third straight year is another signal that the AI infrastructure scramble has moved well beyond simply finding chips. Somebody has to turn all that expensive compute into services customers can provision, use, measure and...

Continue Reading
Winter Leaks Can Lock In Tarrant Sewer Costs for 2027

Updated Category News Views 97

Silent toilet seepage has a nasty habit of turning winter into a twelve-month utility hangover. Tarrant County homeowners are heading into the period when some local cities use household water consumption to calculate residential sewer charges for the following year. That is not the sort of detail anybody enjoys thinking about during the holidays, but ignoring it can be...

Continue Reading
Borr’s Q3 Presentation Puts Jack-Up Investors on Watch

Updated Category News Views 106

Jack-up drilling is a rough business to judge from a calendar invite, but Borr Drilling has put a useful marker in the sand. The company is scheduled to present financial results for the three and nine months ended September 30, 2026, at 09:00 New York time, or 15:00 CET, on Thursday, November 19. For holders of BORR, this is less about ceremonial webcast chatter and more...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 174

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Titan Center Lease Gives Pocatello Retail Some Teeth

Updated Category News Views 157

A chicken sandwich lease is not usually a redevelopment thesis, yet Titan Center's new Chick-fil-A deal carries more weight than a routine restaurant announcement. Industrial Realty Group has landed a nationally recognized tenant at the entrance to a property with a long, complicated industrial past. In a smaller market, that sort of win can matter. Retail momentum is...

Continue Reading

Top 5 Most Recently Viewed Articles

Boeing's Stock Recovery Sparks Interest in Direxion ETFs

Updated Category News Views 184

Boeing's Efforts to Restore Credibility Boeing Co (NYSE: BA) stands as an iconic figure in the aerospace and defense industry, playing a critical role in both U.S. and global markets. The company's recent management strategies have seemingly succeeded in resonating with investors, contributing to an impressive rise in BA stock, which has surged over 24% year-to-date. In...

Continue Reading
Alliance Witan PLC Unveils Latest Net Asset Value Insights

Updated Category News Views 118

Understanding Alliance Witan PLC's Net Asset Value Alliance Witan PLC provides investors with a key financial metric known as the Net Asset Value (NAV), which represents the value of its assets minus liabilities. These values are crucial for shareholders looking to assess the company's financial health and performance. Latest NAV Figures Recently, it was reported that at...

Continue Reading
MSPAlliance Advocates for Cyber Immunity to Enhance Security

Updated Category News Views 76

Enhancing Cybersecurity Through State Legislation In light of the escalating threat of cyberattacks, MSPAlliance, the International Association of Cloud & Managed Service Providers, has taken the initiative to propose a framework for state cyber immunity legislation. This legislation is designed to motivate organizations to embrace meaningful cybersecurity practices by...

Continue Reading
Investors of Applied Therapeutics, Inc. (APLT) Take Action Now

Updated Category News Views 135

Urgent Call to Action for Affected Investors Investors who have faced financial losses from Applied Therapeutics, Inc. (NASDAQ: APLT) are strongly urged to take immediate action regarding a significant legal case. The Law Offices of Howard G. Smith has announced a deadline for filing a lead plaintiff motion, providing an essential opportunity to participate in a class...

Continue Reading
Leap Partners Expands Reach with New Acquisition in NC Market

Updated Category News Views 188

Leap Partners Expands Its Portfolio in North Carolina In a strategic move, Leap Partners has made headlines by acquiring Master Plumbers Heating and Cooling, solidifying its presence in North Carolina. This acquisition not only underscores Leap Partners' commitment to growth but also enhances its operational capabilities in the state. Strengthening Community Connections...

Continue Reading